Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Echo Therapeutics Inc. Stories

2011-08-12 07:00:00

PHILADELPHIA, Aug. 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at www.echotx.com. Recent Corporate Highlights: In May...

2011-08-09 07:00:00

PHILADELPHIA, Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at www.echotx.com. The new video showcases the features and ease of use of the Symphony continuous glucose...

2011-08-08 07:00:00

PHILADELPHIA, Aug. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY. Echo Therapeutics received notice that...

2011-08-02 07:00:00

PHILADELPHIA, Aug. 2, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that Marshall ('Mac') D. Deweese, who has more than fifteen years of experience in blood glucose monitoring systems, has joined Echo Therapeutics' management team as part of the company's plan...

2011-06-28 06:30:00

PHILADELPHIA, June 28, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude(TM) SkinPrep System for transdermal drug delivery, is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market. Echo expects its shares to begin trading on NASDAQ on Wednesday, June 29, 2011. The Company will...

2011-06-03 07:30:00

PHILADELPHIA, June 3, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Jefferies 2011 Global Healthcare Conference. Dr. Mooney will make a corporate...

2011-05-23 07:00:00

PHILADELPHIA, May 23, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced that it has received the key components of its next generation Symphony tCGM System design. This newly-engineered design is currently undergoing its final functionality testing. The updated Symphony...

2011-05-16 07:30:00

PHILADELPHIA, May 16, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that Christopher P. Schnittker, CPA, joined the company as its Chief Financial Officer. Mr. Schnittker is a senior executive with more than twenty years of financial management, reporting and...

2011-05-16 07:00:00

PHILADELPHIA, May 16, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC BB: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced results for the period ended March 31, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at www.echotx.com. Recent Corporate Highlights: Echo...

2011-05-10 07:30:00

FRANKLIN, Mass., May 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at SEVEN; Noble Financial Markets' Seventh Annual Equity Conference. Dr. Mooney...